


Northern Germany united in the Fight against Cancer

# Letters of Support

for the application of the University Cancer Center Hamburg (UCCH)  
as a candidate site for the strategic concept development of the  
extended National Center for Tumor Diseases (NCT)

February 27, 2020



## List of Letters of Support (LOS)

<b>LOS 1</b>	University Medical Center Schleswig-Holstein.....	1
<b>LOS 2</b>	Pius Hospital Oldenburg and Klinikum Oldenburg.....	2
<b>LOS 3</b>	Carl von Ossietzky University Oldenburg.....	3
<b>LOS 4</b>	University Medical Center Rostock.....	4
<b>LOS 5</b>	National Association BNHO e.V., regional section Hamburg.....	6
<b>LOS 6</b>	Network Oncology Centers Schleswig-Holstein.....	7
<b>LOS 7</b>	Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V. ....	8
<b>LOS 8</b>	Patient Support Groups of the UCCH.....	10
<b>Preamble</b>	Patient Advisory Board UCCH.....	12



UNIVERSITÄTSKLINIKUM  
Schleswig-Holstein

UKSH, Campus Kiel, Arnold-Heller-Straße 3, 24105 Kiel

Prof. Dr. med Carsten Bokemeyer  
University Cancer Center Hamburg  
University Hospital Hamburg Eppendorf  
Martinistr. 52  
20246 Hamburg

**Prof. Dr. Jens Scholz**  
**Vorstandsvorsitzender**

E-Mail: [vv@uksh.de](mailto:vv@uksh.de)  
[www.uksh.de](http://www.uksh.de)

**Campus Kiel**  
Arnold-Heller-Straße 3 · Haus V40 · 24105 Kiel  
Tel.: 0431 500 -10001, Fax: - 10004

**Campus Lübeck**  
Maria-Goeppert-Str. 7a · 23538 Lübeck  
Tel.: 0451 500 -10002, Fax: - 10008

Datum: 14.2.2020

**Letter of Support for the application of UCCH as a future NCT-site**

The University Medical Center Schleswig-Holstein with its two sites Kiel and Lübeck strongly and actively supports the application of the University Cancer Center Hamburg (UCCH) as a future NCT-site (Network of the National Center for Tumor Diseases) within the funding program of the Federal Ministry of Education and Research (BMBF).

In recognition of its outstanding contribution in basic and clinical cancer research as well as in clinical cancer care and prevention, the UCCH currently serves as the only cancer center of excellence funded by the German Cancer Aid (DKH) in Northern Germany. Facing the emerging challenges in personalized medicine, innovation in cancer care, and the growing cancer incidence in general, we started a strategic cooperation initiative of the UCCH and the UKSH in early 2019 with the clear aim to develop a fully functional cancer center at UKSH, which will fulfill all the requirements of an Oncology Center of Excellence in the future. Through regular workshops and joint task forces we are already aligning infrastructures to enable patients in Northern Germany to participate in innovative clinical trials and personalized cancer care. Strategic alliances are also being developed in major areas of research to advance a strong translational research program on personalized oncology for Northern Germany. We will support the NCT application of UCCH with innovative cancer research programs and research platforms located at the universities in Kiel and Lübeck respectively.

In case of a positive decision on an NCT-site in Hamburg, the already initiated cooperation between the UCCH and the UKSH would not only be strengthened, but the UKSH expresses its strong will to contribute with patient cohorts and referral of patients for joint trials on personalized medicine to enhance the positive development of an NCT site at Hamburg. Thus, the UKSH fully supports this application, which will help integrate Northern Germany's excellent translational cancer research expertise into the NTC Network and provide excellent personalized cancer care for the population of Northern Germany.

With kind regards

Prof. Dr. Jens Scholz  
CEO  
UKSH

Prof. Dr. Claudia Baldus  
Director of the Medical Clinic II,  
Hematology and Oncology  
Head of the Oncology Centre  
UKSH Campus Kiel

Prof. Dr. Nikolas von Bubnoff  
Director of the Department of  
Hematology and Oncology  
Head of the Oncology Centre  
UKSH Campus Lübeck

Universitätsklinikum  
Schleswig-Holstein  
Anstalt des  
öffentlichen Rechts

Vorstand:  
Prof. Dr. Jens Scholz  
(Vorsitzender)  
Peter Pansegrau  
Michael Kiens  
Prof. Dr. Ulrich Stephani  
Prof. Dr. Christopher Baum

Bankverbindung:  
Förde Sparkasse  
IBAN: DE14 2105 0170 0000 1002 06  
SWIFT/BIC: NOLA DE 21 KIE  
Commerzbank AG  
IBAN: DE17 2308 0040 0300 0412 00  
SWIFT/BIC: DRES DE FF 230





Medizinischer Campus  
Universität Oldenburg

Letter of support

The Pius Hospital Oldenburg and the Klinikum Oldenburg, both representing the clinical sites of the European Medical School Oldenburg-Groningen, strongly support the application of the UCCH Hamburg as a future site of a German NCT (National Center for Tumor Diseases) network.

The UCCH has been acknowledged and funded as a Cancer Center of Excellence by the German Cancer Aid (DKH) for the last 11 years (2009-2021) and serves as a unique academic partner providing excellent multi-disciplinary and personalized cancer care, clinical trial activities for specific and/or large cohorts of cancer patients as well as internationally competitive and high-output translational research programs.

The establishment of the UCCH as a site within the German NCT consortium would allow patients of a catchment area of approximately 10 million inhabitants in Northern Germany an optimized and unrestricted access to important innovations in cancer treatment, in particular with regards to personalized cancer care and participation in specialized innovative early clinical trials. The University Medicine Oldenburg with their Cancer Centers is dedicated to interact with a potential NCT site in Hamburg with respect to our strong impact in large patient cohorts with lung cancer, by cooperation in the prostate cancer program and by identifying patients with uncommon / rare tumor mutations for trial participation at the NCT site. Thus, the Klinikum Oldenburg and the Pius Hospital strongly support the UCCH application as an NCT site with the common aim of significantly improving the quality of cancer care and translational research in the northern region of Germany.

**Vorstand**

Rahel-Straus-Str. 10  
26133 Oldenburg

Telefon:  
Vermittlung  
0441-403-0  
Durchwahl  
0441-403-2223  
Telefax  
0441-403-2786

Datum:  
13.02.2020

Pius-Hospital Oldenburg

Klinikum Oldenburg AöR

Elisabeth Sandbrink  
Geschäftsführerin

Rainer Schoppik  
Vorstand

Prof. Frank Griesinger  
Universitätsklinik für Innere  
Medizin – Onkologie

Prof. Claus-Henning Köhne  
Universitätsklinik für Innere  
Medizin – Onkologie und Hämatologie



CARL VON OSSIETZKY UNIVERSITÄT OLDENBURG · 26111 OLDENBURG


**Bewerbung des Universitären Cancer Center Hamburg (UCCH) als NCT-Standort**

**Erklärung**

Sehr geehrte Damen und Herren,

wir begrüßen es sehr, dass Frau Prof. Dr. med. Andrea Morgner-Miehlke als stellv. Direktorin des Universitären Cancer Center Hamburg (UCCH) diese Initiative ergreift und die fachliche Expertise des UCCH aktiv in das BMBF Vorhaben als NCT (Nationales Centrum für Tumorerkrankungen) -Standort einbringt. Neben der Relevanz des NCT-Standortes Hamburg für die Region Norddeutschland im Allgemeinen sind wir davon überzeugt, dass ein NCT-Standort Hamburg auch wichtige Impulse für onkologische Forschungslandschaft an umgebenden Universitäten wie der Carl von Ossietzky Universität Oldenburg setzen wird.

Mit freundlichen Grüßen,

  
Prof. Dr. Dr. Hans Michael Piper  
Präsident

  
Prof. Dr. Hans Gerd Nothwang  
Dekan FakVI - Medizin und Gesundheitswissenschaften

DER PRÄSIDENT

IHR ZEICHEN / NACHRICHT VOM

UNSER ZEICHEN / NACHRICHT VOM

SACHBEARBEITUNG

SEKRETARIAT

Ina Abeler, Birgitta Niese

TELEFONDURCHWAHL

Präsident: 0441 798-5450

Sekretariat: 0441 798-5452 / -5453

E-MAIL

praesident@uni-oldenburg.de

sekretariat.p@uni-oldenburg.de

OLDENBURG, 13.02.2020

PRÄSIDIUM

POSTANSCHRIFT

D-26111 Oldenburg

PAKETANSCHRIFT

Ammerländer Heerstraße 114 - 118

D-26129 Oldenburg

TELEFON

0441 798-5464

FAX

0441 798-2399

INTERNET

www.uni-oldenburg.de

BANKVERBINDUNG

Landessparkasse zu Oldenburg (LzO)

BIC: SLZODE22

IBAN:DE46 2805 0100 0001 9881 12



Universitätsmedizin Rostock PF 10 08 88 · D-18055 Rostock


To  
Prof. Dr. Carsten Bokemeyer  
UCCH

**Medizinische Klinik III - Klinik für  
Hämatologie, Onkologie,  
Palliativmedizin  
Zentrum für Innere Medizin**

Ernst-Heydemann-Str. 6  
18057 Rostock

**Direktor:**  
Prof. Dr. med. Christian Junghanß

**Sekretariat-Direktion**  
Telefon +49 381 494-7421  
Telefax +49 381 494-7422  
direktion.onkologie@med.uni-rostock.de



Rostock, 06.02.2020

## Letter of Support

Dear Ladies and Gentlemen,  
the University Medical Center Rostock strongly supports the application of the University Cancer Center Hamburg (UCCH) as a future NCT-site (Network of National Tumor Centers) within the funding program of the Federal Ministry of Education and Research (BMBF).

Over the past 10 years the University Cancer Center Hamburg has demonstrated its dedication to cancer research, translational oncology and cancer care with broad outreach activities and a national and international recognizable scientifically clinical profile.

With an approximate distance of 170 km between the two cities, a Northern German NCT-site in Hamburg would allow patients from the area of Rostock to participate in specialized oncological innovative trials. This would strengthen the cooperation between the University Centers at Hamburg and Rostock and give us the unique infrastructure to develop a common oncologic strategy for research and patient care in Northern Germany.

Universitätsmedizin Rostock – rechtsfähige Teilkörperschaft der Universität Rostock · www.med.uni-rostock.de  
Vorstand: Harald Jeguschke, Annett Laban, Prof. Dr. Emil C. Reisinger, Prof. Dr. Christian Schmidt · Aufsichtsratsvorsitzender: Mathias Brodtkorb  
UST-IdNr: DE 246 101 670 · Deutsche Bundesbank Filiale Rostock · IBAN: DE1613000000013001531 · BIC: MARKDEF1130

As the University Medical Centers of Rostock and Greifswald are currently establishing the Comprehensive Cancer Center Mecklenburg-Vorpommern (CCC-MV) a positive decision on a NCT-site in Hamburg would foster NCT activities within the Northern Region of Germany.

Sincerely Yours,



Prof. Dr. Christian Junghanß

Chair CCC-MV (Rostock)



BNHO-HH e. V. • Dr. E. Engel • Mörkenstraße 47 • 22767 Hamburg

**University Cancer Center Hamburg (UCCH)  
Universitätskrankenhaus Eppendorf (UKE)  
Martinistrasse 52  
20246 Hamburg**

**Regionalverband Hamburg e.V.  
Der Vorstand**

Vorsitzender:  
Dr. Erik Engel  
Mörkenstraße 47  
22767 Hamburg  
Tel.: 0 40- 38 02 12 - 30  
Fax.: 0 40- 38 02 12 - 39  
[erik.engel@hopa-hamburg.de](mailto:erik.engel@hopa-hamburg.de)

Stellvertretender Vorsitzender:  
Dr. Jan Wierecky  
Ballindamm 3  
20095 Hamburg  
Tel.: 0 40- 35 71 77 7- 0  
Fax.: 0 40- 35 71 77 7- 10  
[wierecky@gmx.de](mailto:wierecky@gmx.de)

Schriftführer:  
Dr. Eray Gökkurt  
Eppendorfer Landstraße 42  
20249 Hamburg  
Tel.: (0) 40- 46 02 001  
Fax.: (0) 40- 47 35 47  
[goekurt@gmail.com](mailto:goekurt@gmail.com)


Hamburg, den 14.02.2020

The private practice based hematologists and oncologists in the metropolitan area of Hamburg – here represented by their regional section of their national association BNHO- are working in a long-term and continuously intensified partnership with the UCCH.

This successful cooperation on several clinical and infrastructural levels including shared multidisciplinary tumor boards, fixed trial network structures and common educational events is documented within a contracted partnership with 19 office-based oncology sites with more than in total 80 oncologists.

The Hamburg office-based oncologists are happy to strongly support the application of the UCCH Hamburg as a site of a German NCT network. With an NCT-site at Hamburg we, we see a unique chance for our patients in an optimized access to innovation in cancer care, especially in personalized medicine and targeted treatments, which we would consequently support with referrals for clinical trials, biobanking and for molecular analyses.

In context of this potential new structure, we also see a unique chance to extend the cooperation in realizing our long-term aim of an establishment of data exchange pathways covering molecular and clinical data in order to establish a consequent longitudinal follow-up registry. This would allow us to contribute to a proposed network with a database in order to enabling a system truly learning from real world clinical care data in terms of continuous knowledge generation.



Dr. med. Erik Engel  
Chairman BNHO HH e.V.





## Letter of Support for the Application of UCCH as a future NCT - site

The NOZ (Netzwerk Onkologischer Zentren) is an independent association of 21 office based oncologists, 8 high volume community hospitals and 2 rehab clinics treating cancer patients in the state of Schleswig-Holstein. The NOZ is dedicated to delivering optimal therapies to nearly 10.000 cancer patients in a predominantly rural region of Northern Germany with only two larger cities (Luebeck and Kiel).

The NOZ strongly supports the application of the UCCH Hamburg as a site of a German NCT network. The UCCH serves currently already as a unique academic partner offering continuous excellence in cancer care in the whole Northern German region. The UCCH has established an extensive network of partner sites and is highly recognized for its successes in translational research, multidisciplinary treatment standards and pathways, clinical trial activities, educational activities and outreach events for physicians as well as for patients.

The establishment of the UCCH as a German NCT site would give many of our patients optimized and unrestricted access to important innovations in cancer treatment, in particular with regards to personalized cancer care and participation in early clinical trials. Moreover, we will follow in our cooperation the aim of establishment a data exchange platform for off-label use of molecular and non-molecular targeted therapies to use results from patient treatment for general knowledge generation, which represents in our view a yet unmet clinical need.

With this letter, the NOZ commits, once the UCCH application to become part of the NCT network is accepted, to a full support of the UCCH in regards of patient referral to clinical trials and the personalized cancer care program.

Even more, we are convinced that the UCCH with its nationwide leadership role in broad cancer entities like prostate cancer, but also in entities with special needs like pediatric cancer or adult leukemias, will substantially strengthen the NCT network initiative.

Luebeck, 20<sup>th</sup> of February 2020

Jens Kisro M.D. PhD  
Head of NOZ

A handwritten signature in black ink, appearing to read 'Jens Kisro', is written over a horizontal line.



**KNACK DEN KREBS**  
Fördergemeinschaft  
Kinderkrebs-Zentrum  
Hamburg e.V.

Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V.  
Gebäude N21 – UKE Martinistraße 52 20246 Hamburg

### To whom it may concern

The *Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V.* has endorsed the Clinic for Pediatric Hematology and Oncology (PHO) at the University Medical Center Hamburg-Eppendorf (UKE) for about 45 years. The non-profit association was founded in 1975 by parents of children with cancer. Under the slogan "KNACK DEN KREBS", it sensitizes the regional public to the topic of children's cancer.

With almost 1,000 members and an annual expenditure between two and three million euros for three statutory purposes and overhead, the fund-raising association provides strong support for children with cancer in the metropolitan region of Hamburg.

Our funds are used to

- a. achieve optimal patient care at the University Medical Center,
- b. provide psychological care and social service to affected patients and families and
- c. promote research, in particular at the *Research Institute Children's Cancer Center Hamburg*.

The government, social security agencies and the UKE should not be released from their duties. Our association helps where there are gaps. In addition to continuous funding e.g. of psychosocial service at the clinic, convincing project applications are often funded on a long-term basis with the aim of converting them into regular funding by the state or health insurances. Successful examples are the establishment of modern clinical diagnostics (liquid biopsy assessment of minimal residual disease) in frontline ALL trials and implementation in health insurance programs, development of an outpatient pediatric palliative care or the testing of telepresence technology to attend school lessons while being treated in clinic or resting at home. Currently, we focus on long-term care for cancer survivors and the promotion of young clinician-scientists.

Our association's commitment to translational as well as basic research in cancer of

pto

**GESCHÄFTSSTELLE**  
Gebäude N21 – UKE  
Martinistraße 52  
20246 Hamburg  
Telefon 040- 25 60 70  
buero@kinderkrebs-hamburg.de  
www.kinderkrebs-hamburg.de

**GESCHÄFTSFÜHRER**  
Dr. Klaus Bublitz

**VORSTAND**  
Dr. Holger Iversen, Vorsitzender  
Stephanie Joebsch  
Catrina Borchardt  
Janet Stegner-Brummer  
Jochen Zingel

**BEIRAT**  
Prof. Dr. Stefan Rutkowski  
Prof. Dr. Ingo Müller

**SPENDEN**  
**Hamburger Sparkasse**  
IBAN DE03 2005 0550 1241 1333 11  
**Sparda-Bank Hamburg**  
IBAN DE29 2069 0500 0005 0092 00  
**Online**  
www.kinderkrebs-hamburg.de/spenden

Gemeinnütziger Verein seit 1975  
Amtsgericht Hamburg VR 8414



KNACK DEN KREBS  
Fördergemeinschaft  
Kinderkrebs-Zentrum  
Hamburg e.V.

Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V.  
Gebäude N21 – UKE Martinistraße 52 20246 Hamburg

childhood is evidenced by the fact that we allocate about 50% of our total funding to cancer research.

In order to use these subsidies in a focused and efficient manner, the *Research Institute Children's Cancer Center Hamburg* was founded in 2006 at the Heinrich-Pette-Institut (HPI) on UKE premises. The Research Institute is a non-profit subsidiary of our association. The Institute provides modern state-of-the art technology on 500 sqm for four research groups working on pediatric leukemia, neurooncology, stem cell transplantation and immunotherapy currently comprising 17 scientists, 16 doctoral students and eight technicians in cooperation with affiliated UKE and HPI. The scientific performance of research groups is evaluated in three-year terms by an international scientific advisory board chaired by the clinical director of the PHO. The institute has been endowed with two professorships funded by our association to strengthen pediatric oncology at the university hospital.

It goes without saying that we support the conceptualization and application of the UKE as a National Center for Tumor Diseases (NCT).

If necessary and to underline our interest in the establishment of a NCT site at the University Medical Center Hamburg we are willing to consider to financially support the integration of the *Research Institute Children's Cancer Center* into a new NCT building and its future operation as we strongly believe in the synergistic effects of structural integration of research and patient care in pediatric and adult oncology to promote translational activities and that this will make a difference in cancer care.

Hamburg in February 2020

Dr. Holger Iversen

Bundesministerium für Bildung und Forschung  
Kapelle-Ufer 1  
11055 Berlin

Hamburg, 04.02.20






**Re: Application of the University Cancer Center Hamburg (UCCH) as a National Center of Tumor diseases**

Dear Sir or Madam,

The assembly of the patients support groups of the University Cancer Center Hamburg (UCCH) would like to strongly express their unrestricted support for the application of the UCCH as a member within the Network of National Tumor Centers in Germany. We have a longstanding cooperation with the UCCH in terms of common educational events, personal counselling as well as involvement in clinical trial questions and pathways on shared decision-making. The UCCH provides tremendous support in many psychological, medical, and social aspects associated with cancer disease. We value the long-term cooperation with the UCCH and acknowledge the UCCH's constant efforts towards patient-participation into the development of the center's different facets. In the case of the development of a NCT site at Hamburg, we will be clearly committed to strengthen this fruitful collaboration even further and will enhance our participation in all relevant aspects of the Cancer Center in the future.

We would thus welcome a National Center for Tumor diseases in the region of Northern Germany, where our activities and groups are located.

With best regards

	Heide Lakemann	Frauenselbsthilfe nach Krebs
	ULRIKE GÖBEL	Aplastische Anämie CPNH e.V.
	Otmar Kodalle	SHB Feiserehekrebs
	Kai-Uwe Pargans-Burkka	Förderverein für Knochenmark- transplantation in Hamburg e.V.
	Arno Jodan	St. ILCO e.V. Landesverband HH+SH

Miranda Blohm Miranda Blohm AdP

Gisela Leunke SHG Blasenkrebs  
Kerstin Nowicki NOWICKI, HEINKE #SH

Brigitte Fiese Brigitte Giese Alliant-gg.Brustkrebs

Walther Prym Walther Prym ProMann<sup>e.V.</sup>

Günther Carl SHG Pimeberg



Preamble Patient Advisory Board p. 1 / 3

The Patient Advisory Board Research for the University Cancer Center Hamburg - an alliance with patient support groups

## **Preamble to the foundation of a Patient Advisory Board *Research* for the UCCH**

The cooperation of the University Cancer Center Hamburg with patient support groups (PSGs) has a long tradition. The diagnosis of a cancer disease and the existential threat it poses to many patients affects diverse areas of life of a patient and his or her environment. Professional medical care at our center is complemented by the advice and support offered by numerous PSGs for those affected and their relatives.

We are aware of the importance of self help for our patients and the overall care for people with cancer and have therefore expanded the Board of Directors of the UCCH to include elected representatives of the cooperating PSGs.

With the establishment of a Patient Advisory Board *Research*, we now want to further strengthen the position of patient representatives to play an active role in clinical and experimental cancer research at our center, beyond the provision of care for cancer patients and their relatives. In this way, we enable an active and direct exchange with the decision makers at the University Cancer Center Hamburg on all aspects concerning cancer patients. We hope to gain an even deeper understanding of the realities and needs of care from the perspective of those affected, in order to be able to meet the actual needs of our patients even better than before. We also hope that the Patient Advisory Board will provide a deeper understanding of the research concepts in cancer medicine and at the same time take better account of the wishes and concerns of patients.

After consultation and in agreement with the elected representatives of the UCCH PSGs, the UCCH's Patient Advisory Board *Research* was founded on February 4, 2020. The founding members of this Patient Advisory Board are the elected PSGs representatives, please see listed below.

The Patient Advisory Board consists of up to 8-10 additional members, who are nominated by the patient representatives in agreement with the UCCH board of directors. The membership in the Patient Advisory Board *Research* is fixed for two years. Re-election is possible. For participation in the three scheduled meetings of the committee per year, a flat-rate reimbursement of 300 Euro per person and year is provided for the patient representatives. For this purpose, a contract is concluded with UCCH/UKE. The advisory board elects a secretary from among its members, who is responsible for taking the minutes of the meetings. The minutes will be agreed upon with the members and the Board of the UCCH.

### ***Tasks and goals of the Patient Advisory Board Research***

#### **Advisory Role**

The Patient Advisory Board of the UCCH advises the UCCH Board of Directors and the physicians and scientists working at the UCCH in matters of cooperation with patient representatives regarding the further development and implementation of cancer research and care.



Universitätsklinikum Hamburg-Eppendorf



The Patient Advisory Board is given the opportunity to review the patient orientation of the UCCH with regard to sustainability and to contribute to ensuring that research and patient care at the UCCH is substantially oriented towards patient benefit.

**Integration into Care and Clinical Research**

The Patient Advisory Board is given the opportunity to inform itself directly about the development of care structures and scientific concepts at the UCCH and to play an active role in the planning of new concepts and make suggestions for improvement. This applies not only to health services research but also to clinical research in particular. In the latter area there is above all the possibility of jointly identifying the need for clinical study protocols. Members of the Patient Advisory Board declare their willingness to support research projects and clinical studies developed by the UCCH in an advisory capacity.

**Strategic Alliances**

The Patient Advisory Board advises the UCCH on the planning of strategic partnerships and the expansion of the existing cooperation network.

**Concerns of the Patient Representatives**

The Patient Advisory Board should be open for the topics and agenda items presented by patient representatives and bring them into the discussion with the physicians and scientists at the UCCH.

**Public Relations**

Patient representatives of the Research Advisory Board may, in agreement with and/or on behalf of the UCCH, participate in press conferences or public events on the topics discussed in the Advisory Board.

The Patient Advisory Board can participate in meetings of the UCCH Board of Directors or other UCCH committees in addition to the fixed meeting dates of the advisory board. The necessity for this is determined in a joint vote.

**Hamburg, February 4, 2020**

**Appointed Patient Representatives are:**

Name of PSG	Name	Signature
Frauenselbsthilfe nach Krebs e.V.	Heide Lakemann	
Aplastische Anämie & PNH e.V.	Ulrike Göbel	
SHG Prostatakrebs Pinneberg	Ernst-Günther Carl	
Förderverein für Knochenmarktransplantation in Hamburg e.V.	Kai-Uwe Parsons Galka	



NetzwerkStatt Krebs	Ines Moegling	<i>Ines Moegling</i>
Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V.	Dorothee Iversen	<i>Dorothee Iversen</i>
Plasmozytom-Myelom Selbsthilfegruppe Hamburg	Jürgen Martens	<i>J. Martens</i>
OVAR-SHG Selbsthilfegruppe Eierstockkrebs	Susanne Engel	<i>Susanne Engel</i>
Sherpa	Katrin Wemheuer	<i>Katrin Wemheuer</i>
Selbsthilfegruppe Speiseröhrenkrebs	Otmar Kodalle	<i>Otmar Kodalle</i>

Cancer Unites /  
Frauenselbsthilfe nach Krebs

Susan Sommerfeld

*Susan Sommerfeld*